BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• 3D Medicines Raises $101M for Cancer Diagnostics and Drugs

  The funding was led by China Reform Holdings and joined by ChinaEquity Group and several unnamed investors.

  November 27, 2017

   · 

  1 min read
• 

  Business

  Boehringer Focuses on RNA

  Boehringer has made a big push into RNA this month.

  November 27, 2017

   · 

  1 min read

   · 

  Karl Thiel
• 

  Business

  Does Genentech Have a New Mega-Blockbuster?

  Genentech’s Hemlibra just got approved but is expected to bring in around $2 billion in peak sales.

  November 27, 2017

   · 

  1 min read

   · 

  Karl Thiel
• 

  Business

  Israel’s Protalix to Slash 20% of Workforce

  Share prices for Protalix are up more than 3 percent this morning after the company reported positive results from its Phase I/II open label extension trial of pegunigalsidase alfa, PRX-102, for the treatment of Fabry disease.

  November 27, 2017

   · 

  2 min read

   · 

  Alex Keown
• Business

  Lee’s Pharm Forms Second China Cancer Partnership With Beijing Shenogen

  In the latest joint effort, Lee’s Pharm will pair its PD-L1 candidate with icaritin.

  November 27, 2017

   · 

  1 min read
• Eisai to Present Latest Data on Perampanel and Rufinamide at 71st American Epilepsy Society Annual Meeting

  Inovelon will be presented at the 71st AES Annual Meeting to be held from December 1 to 5, 2017 in Washington D.C. in the United States.

  November 27, 2017

   · 

  2 min read
• 

  Business

  Our Insider HHS Secretary

  A look at President Trump’s new pick for HHS Secretary.

  November 27, 2017

   · 

  1 min read

   · 

  Karl Thiel
• 

  Policy

  Stem Cells Ready for Prime Time?

  A look at the FDA’s long-awaited guidelines on how it will regulate regenerative medicine products, including stem cells.

  November 27, 2017

   · 

  1 min read

   · 

  Karl Thiel
• 

  Drug Development

  Innate Tanked as Drug Combined With Bristol-Myers’ Opdivo Flopped in Study

  While lirilumab was shown to be well-tolerated, it did not demonstrate efficacy in treating that patient population.

  November 27, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  ASH Heats Up, Plus Alkermes’ Huge I-Told-Ya-So

  The drug developed by Alkermes took a lot of flack but proved effective in a recent study.

  November 27, 2017

   · 

  1 min read

   · 

  Karl Thiel